vs
Side-by-side financial comparison of Altimmune, Inc. (ALT) and Pyxis Oncology, Inc. (PYXS). Click either name above to swap in a different company.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based immuno-oncology therapies for hard-to-treat solid tumors and hematological malignancies. Its core pipeline features multiple candidates designed to activate the human immune system against cancer cells, with primary operations and target markets across North America and select European regions.
ALT vs PYXS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0K | $0 |
| Net Profit | — | $-22.0M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | 420.0% | — |
| Net Profit YoY | -18.0% | -3.8% |
| EPS (diluted) | — | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0K | — | ||
| Q3 25 | $5.0K | $0 | ||
| Q2 25 | $5.0K | $2.8M | ||
| Q1 25 | $5.0K | — | ||
| Q4 24 | $5.0K | — | ||
| Q3 24 | $5.0K | $0 | ||
| Q2 24 | $5.0K | $0 | ||
| Q1 24 | $5.0K | $16.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-19.0M | $-22.0M | ||
| Q2 25 | $-22.1M | $-18.4M | ||
| Q1 25 | $-19.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-22.8M | $-21.2M | ||
| Q2 24 | $-24.6M | $-17.3M | ||
| Q1 24 | $-24.4M | $-3.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 97.1% |
| Q4 25 | — | — | ||
| Q3 25 | -417180.0% | — | ||
| Q2 25 | -458440.0% | -700.4% | ||
| Q1 25 | -436300.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -495340.0% | — | ||
| Q2 24 | -534900.0% | — | ||
| Q1 24 | -535880.0% | -34.7% |
| Q4 25 | — | — | ||
| Q3 25 | -380280.0% | — | ||
| Q2 25 | -442920.0% | -650.9% | ||
| Q1 25 | -391500.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -456900.0% | — | ||
| Q2 24 | -492800.0% | — | ||
| Q1 24 | -487880.0% | -20.2% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.21 | $-0.35 | ||
| Q2 25 | $-0.27 | $-0.30 | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.32 | $-0.35 | ||
| Q2 24 | $-0.35 | $-0.29 | ||
| Q1 24 | $-0.34 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $273.5M | $76.3M |
| Total DebtLower is stronger | $34.3M | — |
| Stockholders' EquityBook value | $224.9M | $68.8M |
| Total Assets | $279.9M | $105.6M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $273.5M | — | ||
| Q3 25 | $210.8M | $76.3M | ||
| Q2 25 | $183.1M | $88.9M | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $131.9M | — | ||
| Q3 24 | $139.4M | $144.8M | ||
| Q2 24 | $164.9M | $155.7M | ||
| Q1 24 | $182.0M | $157.0M |
| Q4 25 | $34.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $224.9M | — | ||
| Q3 25 | $185.6M | $68.8M | ||
| Q2 25 | $161.4M | $87.6M | ||
| Q1 25 | $142.2M | — | ||
| Q4 24 | $123.5M | — | ||
| Q3 24 | $133.4M | $153.7M | ||
| Q2 24 | $152.5M | $169.8M | ||
| Q1 24 | $172.9M | $184.2M |
| Q4 25 | $279.9M | — | ||
| Q3 25 | $218.4M | $105.6M | ||
| Q2 25 | $190.3M | $123.2M | ||
| Q1 25 | $157.3M | — | ||
| Q4 24 | $139.3M | — | ||
| Q3 24 | $147.9M | $195.3M | ||
| Q2 24 | $173.3M | $208.4M | ||
| Q1 24 | $188.4M | $220.2M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.5M | $-13.3M |
| Free Cash FlowOCF − Capex | $-67.5M | — |
| FCF MarginFCF / Revenue | -259792.3% | — |
| Capex IntensityCapex / Revenue | 42.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.5M | — | ||
| Q3 25 | $-11.9M | $-13.3M | ||
| Q2 25 | $-19.4M | $-17.3M | ||
| Q1 25 | $-16.8M | — | ||
| Q4 24 | $-79.8M | — | ||
| Q3 24 | $-27.1M | $-14.7M | ||
| Q2 24 | $-18.1M | $-3.0M | ||
| Q1 24 | $-16.4M | $-20.7M |
| Q4 25 | $-67.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-20.9M |
| Q4 25 | -259792.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -129.7% |
| Q4 25 | 42.3% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
